Texas Tech University Health Science Center of El Paso
Welcome,         Profile    Billing    Logout  
 3 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gupta, Vikas
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
01/25
01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
03/26
03/26
MPN-RC 119, NCT04281498: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Completed
2
6
Canada, US
Ruxolitinib, Enasidenib
John Mascarenhas, Celgene Corporation, Incyte Corporation, Myeloproliferative Neoplasms Research Consortium, National Institutes of Health (NIH), National Cancer Institute (NCI)
Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis, IDH2 Mutation
05/23
05/23
NCT05074355: Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

Recruiting
2
40
Canada
Azacitidine, Venetoclax
University Health Network, Toronto
Myeloproliferative Neoplasm
05/25
12/25
ALLO-BAT, NCT04217356: Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis

Recruiting
N/A
90
Canada
Hematopoietic stem cell transplant, Ruxolitinib, JAKAVI, Hydroxyurea
University Health Network, Toronto
Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer
08/25
02/26
NCT02760238: Myeloproliferative Neoplasms (MPNs) Patient Registry

Recruiting
N/A
5000
Canada
Observational
University Health Network, Toronto
Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myelomonocytic, Juvenile, Chronic Eosinophilic Leukemia-not Otherwise Specified, Myelodysplastic-Myeloproliferative Diseases, Neoplasms, Leukemia, Myelomonocytic, Chronic
10/27
10/27
Alba, Israel
START, NCT03021928: Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

Active, not recruiting
3
200
US
Time-To-Treatment Randomization
University of Texas at Austin, Lone Star Stroke Research Consortium, Texas Department of State Health Services
Stroke
08/23
12/23
ENDOLOW, NCT04167527: Endovascular Therapy for Low NIHSS Ischemic Strokes

Recruiting
2/3
200
Europe, Canada, US
Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device, EmboTrap III, Initial medical management (iMM)
Emory University, University of Calgary, University of Cincinnati, Heidelberg University, Children's Hospital Medical Center, Cincinnati
Cerebral Ischemia
12/24
12/24

Download Options